Intracarotid VP-16 in malignant brain tumors

Lynn G. Feun; Ya Yen Lee; Wai Kwan Alfred Yung; Niramol Savaraj; Sidney Wallace

doi:10.1007/BF00195611

Intracarotid VP-16 in malignant brain tumors

Lynn G. Feun, Ya Yen Lee, Wai Kwan Alfred Yung, Niramol Savaraj, Sidney Wallace

Neuro-Oncology

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Twenty-eight patients with malignant brain tumors (16 with primary brain tumors and 12 with brain metastases) progressing after cranial irradiation with or without chemotherapy received varying doses of intracarotid VP-16. Courses of therapy were repeated every 4 weeks along with computerized axial tomography scan and neurologic examination. Of 15 evaluable patients with primary malignant brain tumors, 1 responded to therapy and 5 had no immediate tumor progression for 2-10 months. None of 12 evaluable patients with brain metastases responded to intracarotid VP-16 although 5 had no immediate tumor progression from 1-4 months. Side effects of treatment were uncommon. Using this route of administration, intracarotid VP-16 does not appear to increase response rates in patients with primary malignant brain tumors, compared with results reported for intravenous VP-16.

Original language	English (US)
Pages (from-to)	397-401
Number of pages	5
Journal	Journal of neuro-oncology
Volume	4
Issue number	4
DOIs	https://doi.org/10.1007/BF00195611
State	Published - Dec 1987

Keywords

VP-16
brain tumors
intracarotid

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/BF00195611

Cite this

@article{c82e269a9b32421a9935fad7e720e2eb,

title = "Intracarotid VP-16 in malignant brain tumors",

abstract = "Twenty-eight patients with malignant brain tumors (16 with primary brain tumors and 12 with brain metastases) progressing after cranial irradiation with or without chemotherapy received varying doses of intracarotid VP-16. Courses of therapy were repeated every 4 weeks along with computerized axial tomography scan and neurologic examination. Of 15 evaluable patients with primary malignant brain tumors, 1 responded to therapy and 5 had no immediate tumor progression for 2-10 months. None of 12 evaluable patients with brain metastases responded to intracarotid VP-16 although 5 had no immediate tumor progression from 1-4 months. Side effects of treatment were uncommon. Using this route of administration, intracarotid VP-16 does not appear to increase response rates in patients with primary malignant brain tumors, compared with results reported for intravenous VP-16.",

keywords = "VP-16, brain tumors, intracarotid",

author = "Feun, {Lynn G.} and Lee, {Ya Yen} and Yung, {Wai Kwan Alfred} and Niramol Savaraj and Sidney Wallace",

year = "1987",

month = dec,

doi = "10.1007/BF00195611",

language = "English (US)",

volume = "4",

pages = "397--401",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - Intracarotid VP-16 in malignant brain tumors

AU - Feun, Lynn G.

AU - Lee, Ya Yen

AU - Yung, Wai Kwan Alfred

AU - Savaraj, Niramol

AU - Wallace, Sidney

PY - 1987/12

Y1 - 1987/12

N2 - Twenty-eight patients with malignant brain tumors (16 with primary brain tumors and 12 with brain metastases) progressing after cranial irradiation with or without chemotherapy received varying doses of intracarotid VP-16. Courses of therapy were repeated every 4 weeks along with computerized axial tomography scan and neurologic examination. Of 15 evaluable patients with primary malignant brain tumors, 1 responded to therapy and 5 had no immediate tumor progression for 2-10 months. None of 12 evaluable patients with brain metastases responded to intracarotid VP-16 although 5 had no immediate tumor progression from 1-4 months. Side effects of treatment were uncommon. Using this route of administration, intracarotid VP-16 does not appear to increase response rates in patients with primary malignant brain tumors, compared with results reported for intravenous VP-16.

AB - Twenty-eight patients with malignant brain tumors (16 with primary brain tumors and 12 with brain metastases) progressing after cranial irradiation with or without chemotherapy received varying doses of intracarotid VP-16. Courses of therapy were repeated every 4 weeks along with computerized axial tomography scan and neurologic examination. Of 15 evaluable patients with primary malignant brain tumors, 1 responded to therapy and 5 had no immediate tumor progression for 2-10 months. None of 12 evaluable patients with brain metastases responded to intracarotid VP-16 although 5 had no immediate tumor progression from 1-4 months. Side effects of treatment were uncommon. Using this route of administration, intracarotid VP-16 does not appear to increase response rates in patients with primary malignant brain tumors, compared with results reported for intravenous VP-16.

KW - VP-16

KW - brain tumors

KW - intracarotid

UR - http://www.scopus.com/inward/record.url?scp=0023118978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023118978&partnerID=8YFLogxK

U2 - 10.1007/BF00195611

DO - 10.1007/BF00195611

M3 - Article

C2 - 3572470

AN - SCOPUS:0023118978

SN - 0167-594X

VL - 4

SP - 397

EP - 401

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 4

ER -

Intracarotid VP-16 in malignant brain tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this